Ticker
$HROW
1 catalyst touching HROW in the last 60 days, newest first, each with the price move that followed.
- 72
Harrow completes TYRVAYA acquisition from Viatris for $30M
Harrow completed acquisition of TYRVAYA (varenicline nasal spray for dry eye disease) from Viatris on October 1, 2026, paying $30 million in cash plus up to $70 million in contingent milestone payments based on net sales through December 2029. This is a material asset acquisition for an ophthalmic drug with FDA approval, expanding HROW's product portfolio, though the $30M upfront is modest relative to typical M&A and actual revenue impact is contingent on future sales performance.
HROW ▲SEC 8-K · 5 Oct 2026, 11:32 UTC
Information only. AURA does not give buy or sell recommendations.